CLSN Celsion Corporation

0.89
-0.01  -2%
Previous Close 0.9
Open 0.9
Price To Book 1.78
Market Cap 26,041,746
Shares 29,257,101
Volume 189,793
Short Ratio
Av. Daily Volume 243,279
Stock charts supplied by TradingView

NewsSee all news

  1. Celsion's OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm

    Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage III/IV Ovarian Cancer

  2. Celsion Corporation Reports 2019 Financial Results and Provides Business Update

    Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 LAWRENCEVILLE, N.J., March 25, 2020 (GLOBE

  3. Celsion's GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency

    Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug

  4. Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020

     Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation

  5. Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer

     R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II Portion of the OVATION 2

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 second analysis due 2Q 2020. Final readout 1Q 2021.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 2 portion to begin enrolling patients in 2H 2020 with patient data and trends due in 2021. PFS data to be reported 12 months following full patient enrolment.
GEN-1 OVATION 2
Ovarian cancer
Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Phase 1b PFS data released October 24, 2018 - PFS of 17.1 months in ITT population.
GEN-1 OVATION 1
Ovarian cancer

Latest News

  1. Celsion's OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm

    Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage III/IV Ovarian Cancer

  2. Celsion Corporation Reports 2019 Financial Results and Provides Business Update

    Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 LAWRENCEVILLE, N.J., March 25, 2020 (GLOBE

  3. Celsion's GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency

    Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug

  4. Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020

     Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation

  5. Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer

     R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II Portion of the OVATION 2

  6. Celsion CEO Issues Letter to Stockholders

    LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company's chairman, president and chief

  7. Celsion Corporation Prices $4.8 Million Registered Direct Offering

    LAWRENCEVILLE, NJ, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) ("Celsion" or the "Company"), today announced it has entered into securities purchase agreements with institutional investors for

  8. Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer

     Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Celsion

  9. Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference

    Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation

  10. Celsion's New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia

    Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou, China's biotech hub, to develop and commercialize innovative cancer therapies starting with ThermoDox®.Agreement

  11. Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

     Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming Development Milestones

  12. Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

    Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB) Unanimously Recommends

  13. Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

    Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver Doxorubicin in

  14. Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019

    Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Celsion

  15. Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer

    GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celsion

  16. Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

    The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis.The Pooled Progression-Free Survival (PFS) Data is Consistent with

  17. Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding

     $2 Million in Additional NOL Sales are Available to the Company in 2020 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Oct. 01, 2019 (GLOBE

  18. Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

    LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and

  19. Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference

    LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the

  20. Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics

    Data show overall survival improvement of 22.5 months with ThermoDox® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox's potential for superior efficacy when combined with a